Theravance Biopharma, Inc. (TBPH) fair value analysis
Nasdaq · Updated 2026-09-07
Theravance Biopharma, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule medicines. The company operates in the United States and conducts research and development activities targeting respiratory, cardiovascular, and other therapeutic areas.
Valuation status
Awaiting full valuationTBPH does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $16.87
- Sector
- Healthcare
- 12-month range
- $14.42–$19.83
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- C
- Leverage
- Low
- RSI zone
- Overbought
- 50/200-day trend
- Downtrend
- 52-week position
- The lower-middle quarter of its range
What our data shows for TBPH
- Our model validated 5 trailing price-to-earnings windows for TBPH, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $14.42–$19.83.
- The 14-day relative strength index sits at an overbought 71.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TBPH
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent TBPH news
TickrTrends' derived news-sentiment signal for TBPH is currently leaning positive, computed from recent coverage.
- OMERS earns $6.9 billion in the first six months of 2026 (manilatimes.net, 2026-08-11)
TickrTrends take: OMERS' strong interim performance in 2026 may have broader implications for healthcare sector investments given the pension fund's significant allocations across institutional portfolios. For TBPH specifically, investors tracking its valuation should monitor whether strong institutional capital flows into healthcare assets create upward pressure on comparable companies. Since TickrTrends is currently awaiting full valuation data on TBPH, developments from major institutional investors like OMERS could provide context for how the broader investment community is positioning itself in the healthcare space. - Zymeworks To Acquire Theravance Biopharma For $929 Mln In Cash Deal, TBPH Stock Down In Pre-Market (rttnews.com, 2026-06-29)
TickrTrends take: Theravance Biopharma's acquisition at a cash price of 929 million dollars provides a concrete valuation benchmark for the company, which TickrTrends is currently assessing as it awaits full valuation analysis. For investors focused on valuation metrics, this transaction establishes a defined exit price that can be compared against TBPH's historical trading valuations and peer multiples in the Healthcare sector. The pre-market stock decline following the announcement suggests market participants are evaluating whether the acquisition price reflects fair value relative to the company's underlying assets and pipeline prospects.
What people are saying
Follow the TBPH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is TBPH stock undervalued?
TBPH does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is TBPH's TickrTrends verdict?
TBPH is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is TBPH overbought or oversold?
TBPH's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.